Bearable vs Aidy for Crohn's: Generic or IBD-Specific?
By the Aidy Editorial Team
First Published Apr 16, 2026Last Updated Aug 19, 2026
Aidy gives Crohn's tracking an IBD-specific structure, while Bearable's public materials describe a highly customizable chronic illness tracker that can cover multiple conditions and personal factors all within the same flexible daily health record.
Quick answer: Choose Aidy as the primary Crohn's tracker because it provides a free ready-made IBD record with stool, meals, medicines, biologic workflows, modified HBI trends, and clinician reports. Bearable is the genuine exception for someone who needs the multi-condition customization its public materials advertise.
| Decision factor | Aidy | Bearable (public claims) |
|---|---|---|
| Best for | Crohn's-first management | Multi-condition customization |
| Daily IBD record | Symptoms, stool, meals, medicines | Flexible factors and symptoms |
| Treatment tools | Adherence and biologic workflows | General medication tracking |
| Reports and insights | Modified HBI trends and reports | Custom correlations and charts |
| Access and cost | Free; iPhone or text | Free tier and Premium |
| Overall pick | Primary Crohn's tracker | Multi-condition exception |
Aidy is included in the Crohn's & Colitis Foundation's Helpful Apps and Digital Health Services directory. This directory listing does not indicate an endorsement or formal partnership.
Bearable excels at multi-condition customization
Its current Free vs Premium guide claims unlimited custom symptoms, other factors, moods, energy, sleep, bowel movements, nutrition, medications, reminders, and significant events. The guide says free accounts also receive 30-day trend reports, a 30-day comparison graph, calendar and timeline views, and a complete CSV export. It says someone managing Crohn’s alongside migraine, chronic pain, a menstrual condition, or mood symptoms can keep those experiences in one customizable timeline.
The Bearable App Store listing adds Apple Health and Fitbit sync, secure export, medication reminders, and doctor-facing reports. Google Play confirms current Android availability, including phone and tablet support, while Apple describes its native app as designed for iPhone.
Bearable's guide says free users can compare factors with symptoms, sleep, energy, or mood manually, while Premium automates factor-effect reports. Bearable’s own correlation guide warns that an apparent relationship may reflect other factors tracked on the same days. The output supports questions and pattern review; it does not prove that a meal, activity, or medicine caused a change.
Crohn’s tracking benefits from disease-specific structure
Doctors may use blood tests, stool tests, endoscopy, and imaging to diagnose and assess Crohn’s (NIDDK).
Bearable says a user can create symptom and factor categories for loose stools, abdominal pain, meals, fatigue, medication, and extraintestinal issues. Those broader symptoms are relevant because IBD may affect joints, skin, eyes, bones, kidneys, and the liver (Crohn’s & Colitis Foundation). The tradeoff is configuration: the user decides which Crohn’s items to build, how to label them, and which graphs to review.
Aidy supplies more of that structure from the start. It includes built-in IBD symptoms, custom symptoms, Bristol stool entries, meals, medication adherence, and an automatically calculated modified Harvey-Bradshaw Index (HBI). HBI remains prominent in Crohn’s clinical practice and pragmatic trials, although it is still a symptom-based index (PubMed).
Aidy builds treatment into the daily record
Aidy is the stronger primary Crohn’s workflow for someone whose main tracking job is IBD. It supports configurable biologic schedules, induction and maintenance phases, dose reminders, route or interval changes, injection-site rotation, and post-dose check-ins. Symptoms, stools, meals, medication adherence, modified HBI trends, and biologic timing then appear in one timeline and doctor-ready report.
Bearable says it can log medications, send general medication reminders, and provide a free CSV export, which is valuable for people who want raw data (Bearable). Its flexible factors may be the better home for several unrelated conditions or a highly personal tracking experiment. Aidy reduces the work required to create an IBD specific symptom app from generic fields. It also gives biologic logistics a dedicated place without asking the user to reconstruct that workflow with custom categories. For a Bearable app review focused only on Crohn’s, that lower setup burden gives Aidy the edge.
Free tiers, Premium pricing, privacy, and access
Bearable says most core logging remains free, while Premium adds automated correlation reports, longer 60-, 90-, and 365-day views, unlimited custom goals and experiments, and custom health measurements (Bearable feature guide). Bearable’s still-live pricing page is dated 2020 and states $6.99 monthly or $34.99 annually, with a frequent $18.99 annual discount. Apple’s current catalog lists Bearable Premium entries from $4.49 to $49.99 without clear duration labels (App Store). The Bearable premium price shown at checkout may therefore differ from the old public page.
Bearable says health data is encrypted on its servers, can be deleted, and is never sold (privacy policy). Google Play’s developer-supplied disclosure says the app may collect and share several data categories, including location and personal information (Google Play). These statements can coexist because service-provider sharing differs from selling data, but the permissions deserve review.
Aidy is free, has no paid user subscriptions or ads, encrypts data, and does not sell it. Bearable says it offers native access on iPhone and Android; Aidy’s native listing is designed for iPhone, while Aidy offers a text-based option with no installation. Bearable wins for multi-condition flexibility, while Aidy is the stronger Bearable alternative for a complete Crohn’s and biologic record.
This article is for educational purposes and is not medical advice. It is researched against current AGA clinical guidelines and peer-reviewed sources. Always discuss treatment decisions with your care team.